DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Schmid P, Park YH, Ferreira M. et al.
KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early triple-negative breast cancer: pathologic complete response in key subgroups and by treatment exposure, residual cancer burden, and breast-conserving surgery.
San Antonio Breast Cancer Symposium; 2019
2019. GS3-03
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.